Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Food Hypersensitivity | 13 | 2025 | 79 | 4.530 |
Why?
|
| Peanut Hypersensitivity | 9 | 2025 | 17 | 2.790 |
Why?
|
| Desensitization, Immunologic | 10 | 2025 | 46 | 2.100 |
Why?
|
| Asthma | 12 | 2022 | 1039 | 2.020 |
Why?
|
| Tobacco Smoke Pollution | 4 | 2016 | 26 | 1.730 |
Why?
|
| Patient Preference | 2 | 2025 | 125 | 1.630 |
Why?
|
| Arachis | 7 | 2025 | 13 | 1.590 |
Why?
|
| Dust | 4 | 2017 | 26 | 1.460 |
Why?
|
| Allergens | 12 | 2025 | 189 | 1.200 |
Why?
|
| Allergy and Immunology | 3 | 2025 | 16 | 1.070 |
Why?
|
| Choice Behavior | 2 | 2025 | 159 | 1.020 |
Why?
|
| Environmental Exposure | 6 | 2017 | 355 | 0.940 |
Why?
|
| Anaphylaxis | 2 | 2023 | 30 | 0.880 |
Why?
|
| Hypersensitivity | 4 | 2021 | 162 | 0.870 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2022 | 39 | 0.850 |
Why?
|
| Insurance Claim Review | 1 | 2024 | 47 | 0.840 |
Why?
|
| Child | 23 | 2025 | 7355 | 0.810 |
Why?
|
| Health Expenditures | 1 | 2024 | 102 | 0.770 |
Why?
|
| Hypersensitivity, Immediate | 3 | 2013 | 64 | 0.770 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2022 | 25 | 0.750 |
Why?
|
| Antigens, Plant | 2 | 2025 | 15 | 0.740 |
Why?
|
| Child, Preschool | 18 | 2025 | 3829 | 0.720 |
Why?
|
| Egg Hypersensitivity | 2 | 2019 | 4 | 0.710 |
Why?
|
| Housing | 5 | 2015 | 50 | 0.700 |
Why?
|
| Humans | 53 | 2025 | 93515 | 0.560 |
Why?
|
| Dermatitis, Atopic | 3 | 2024 | 65 | 0.550 |
Why?
|
| Poverty | 3 | 2016 | 193 | 0.540 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 168 | 0.530 |
Why?
|
| United States | 14 | 2025 | 7622 | 0.530 |
Why?
|
| 2S Albumins, Plant | 1 | 2017 | 1 | 0.520 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 579 | 0.520 |
Why?
|
| Glycoproteins | 2 | 2017 | 220 | 0.500 |
Why?
|
| Environmental Monitoring | 3 | 2014 | 89 | 0.490 |
Why?
|
| Pandemics | 2 | 2021 | 873 | 0.480 |
Why?
|
| Microbiota | 2 | 2018 | 425 | 0.470 |
Why?
|
| Pediatrics | 1 | 2019 | 385 | 0.450 |
Why?
|
| Adolescent | 13 | 2025 | 9606 | 0.420 |
Why?
|
| Pyroglyphidae | 2 | 2013 | 15 | 0.420 |
Why?
|
| Eczema | 1 | 2014 | 10 | 0.410 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2014 | 56 | 0.400 |
Why?
|
| Dietary Supplements | 1 | 2014 | 131 | 0.390 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 81 | 0.390 |
Why?
|
| Allergists | 2 | 2025 | 5 | 0.380 |
Why?
|
| Female | 22 | 2025 | 48702 | 0.360 |
Why?
|
| Air Pollution, Indoor | 4 | 2014 | 80 | 0.350 |
Why?
|
| Angioedema | 1 | 2011 | 4 | 0.350 |
Why?
|
| Bacteria | 1 | 2015 | 509 | 0.350 |
Why?
|
| Plant Proteins | 2 | 2025 | 129 | 0.340 |
Why?
|
| Familial Mediterranean Fever | 1 | 2010 | 4 | 0.330 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 1 | 2010 | 2 | 0.330 |
Why?
|
| Stomatitis, Aphthous | 1 | 2010 | 4 | 0.330 |
Why?
|
| Pharyngitis | 1 | 2010 | 15 | 0.330 |
Why?
|
| Male | 19 | 2025 | 44557 | 0.320 |
Why?
|
| Retrospective Studies | 7 | 2024 | 10164 | 0.320 |
Why?
|
| Models, Theoretical | 1 | 2012 | 494 | 0.310 |
Why?
|
| Infant | 7 | 2025 | 3220 | 0.310 |
Why?
|
| Young Adult | 5 | 2025 | 6930 | 0.310 |
Why?
|
| Administration, Oral | 5 | 2022 | 657 | 0.300 |
Why?
|
| Smoking | 1 | 2013 | 648 | 0.300 |
Why?
|
| Medicaid | 2 | 2022 | 258 | 0.280 |
Why?
|
| Surveys and Questionnaires | 2 | 2025 | 2802 | 0.250 |
Why?
|
| Rhinitis, Allergic | 2 | 2019 | 52 | 0.240 |
Why?
|
| Double-Blind Method | 4 | 2025 | 1729 | 0.240 |
Why?
|
| Immune Tolerance | 2 | 2019 | 375 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2025 | 394 | 0.220 |
Why?
|
| Food Supply | 2 | 2021 | 31 | 0.210 |
Why?
|
| Epinephrine | 2 | 2021 | 92 | 0.210 |
Why?
|
| Adult | 10 | 2025 | 27918 | 0.200 |
Why?
|
| Health Resources | 1 | 2024 | 80 | 0.200 |
Why?
|
| Air Microbiology | 2 | 2014 | 5 | 0.200 |
Why?
|
| Caregivers | 1 | 2025 | 180 | 0.200 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1847 | 0.190 |
Why?
|
| Middle Aged | 7 | 2025 | 27573 | 0.190 |
Why?
|
| Fungi | 2 | 2014 | 67 | 0.190 |
Why?
|
| Skin Tests | 1 | 2022 | 46 | 0.190 |
Why?
|
| Food | 2 | 2022 | 92 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 624 | 0.190 |
Why?
|
| Vocabulary, Controlled | 1 | 2022 | 11 | 0.180 |
Why?
|
| Albuterol | 1 | 2022 | 35 | 0.180 |
Why?
|
| Probiotics | 2 | 2024 | 92 | 0.180 |
Why?
|
| Early Diagnosis | 1 | 2022 | 135 | 0.180 |
Why?
|
| Food Assistance | 1 | 2021 | 8 | 0.180 |
Why?
|
| Data Collection | 1 | 2023 | 370 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 391 | 0.170 |
Why?
|
| Kansas | 3 | 2016 | 7 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2022 | 176 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1931 | 0.170 |
Why?
|
| Comorbidity | 1 | 2024 | 1007 | 0.160 |
Why?
|
| Skin | 1 | 2024 | 578 | 0.160 |
Why?
|
| Terminology as Topic | 2 | 2018 | 218 | 0.160 |
Why?
|
| Prevalence | 2 | 2014 | 1321 | 0.160 |
Why?
|
| Journal Impact Factor | 1 | 2019 | 15 | 0.150 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 39 | 0.150 |
Why?
|
| Egg Proteins, Dietary | 1 | 2019 | 1 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2020 | 83 | 0.150 |
Why?
|
| Machine Learning | 1 | 2022 | 341 | 0.150 |
Why?
|
| Prebiotics | 1 | 2018 | 8 | 0.150 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 110 | 0.150 |
Why?
|
| Fatty Acids, Volatile | 1 | 2018 | 35 | 0.140 |
Why?
|
| Hospitalization | 1 | 2024 | 937 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2024 | 2479 | 0.140 |
Why?
|
| Collagen Type V | 1 | 2017 | 3 | 0.130 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2017 | 9 | 0.130 |
Why?
|
| Skin Abnormalities | 1 | 2017 | 12 | 0.130 |
Why?
|
| Aged | 4 | 2025 | 20434 | 0.130 |
Why?
|
| Eye Abnormalities | 1 | 2017 | 41 | 0.130 |
Why?
|
| Cross Reactions | 1 | 2017 | 113 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2016 | 23 | 0.120 |
Why?
|
| Joint Instability | 1 | 2017 | 99 | 0.120 |
Why?
|
| Disease Progression | 2 | 2020 | 1531 | 0.120 |
Why?
|
| Biological Products | 1 | 2018 | 178 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2014 | 711 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2016 | 77 | 0.120 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 53 | 0.120 |
Why?
|
| Genes, Bacterial | 1 | 2015 | 150 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 206 | 0.110 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2015 | 259 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2014 | 87 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2017 | 917 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 234 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2014 | 104 | 0.100 |
Why?
|
| Administration, Cutaneous | 2 | 2025 | 61 | 0.100 |
Why?
|
| Fish Oils | 1 | 2014 | 15 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 557 | 0.100 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 101 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 1 | 2014 | 35 | 0.100 |
Why?
|
| Antigens, Dermatophagoides | 2 | 2013 | 11 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 148 | 0.100 |
Why?
|
| Food Contamination | 1 | 2012 | 35 | 0.090 |
Why?
|
| Immune System | 1 | 2013 | 101 | 0.090 |
Why?
|
| Disease Reservoirs | 1 | 2012 | 23 | 0.090 |
Why?
|
| Risk | 1 | 2014 | 657 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2014 | 255 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2016 | 697 | 0.090 |
Why?
|
| Complement C1 Inactivator Proteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Angioedemas, Hereditary | 1 | 2011 | 2 | 0.090 |
Why?
|
| Complement C4 | 1 | 2011 | 8 | 0.090 |
Why?
|
| Animals | 6 | 2024 | 28155 | 0.090 |
Why?
|
| Urticaria | 1 | 2011 | 15 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2013 | 108 | 0.090 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 893 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 537 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2014 | 565 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 920 | 0.080 |
Why?
|
| Phylogeny | 1 | 2015 | 1266 | 0.080 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2009 | 8 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2009 | 19 | 0.070 |
Why?
|
| Family Practice | 1 | 2009 | 73 | 0.070 |
Why?
|
| Pregnancy | 1 | 2014 | 3147 | 0.060 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 373 | 0.060 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 67 | 0.060 |
Why?
|
| Bezoars | 1 | 2005 | 3 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2006 | 74 | 0.060 |
Why?
|
| Rubber | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pica | 1 | 2005 | 14 | 0.060 |
Why?
|
| Intestinal Obstruction | 1 | 2005 | 93 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2006 | 172 | 0.050 |
Why?
|
| Defibrillators, Implantable | 1 | 2006 | 181 | 0.050 |
Why?
|
| Epitopes | 1 | 2025 | 254 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2023 | 80 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2006 | 350 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2023 | 96 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 168 | 0.050 |
Why?
|
| Iowa | 1 | 2022 | 33 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 26 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 429 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2023 | 124 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 82 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 77 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2465 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 142 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2020 | 85 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2018 | 42 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 259 | 0.030 |
Why?
|
| beta-Thalassemia | 1 | 1997 | 6 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 291 | 0.030 |
Why?
|
| Joints | 1 | 2017 | 32 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 149 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1997 | 187 | 0.030 |
Why?
|
| Face | 1 | 2017 | 109 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 295 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 141 | 0.030 |
Why?
|
| Risk Factors | 3 | 2014 | 5899 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1997 | 182 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 44 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 59 | 0.030 |
Why?
|
| Mutation | 2 | 2017 | 4272 | 0.030 |
Why?
|
| Missouri | 1 | 2014 | 18 | 0.030 |
Why?
|
| Genes, rRNA | 1 | 2014 | 7 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1906 | 0.030 |
Why?
|
| Exome | 1 | 2014 | 141 | 0.030 |
Why?
|
| Genes, Fungal | 1 | 2014 | 62 | 0.030 |
Why?
|
| Cities | 1 | 2014 | 57 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2014 | 469 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1301 | 0.020 |
Why?
|
| Arthropod Proteins | 1 | 2013 | 8 | 0.020 |
Why?
|
| United States Environmental Protection Agency | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2013 | 88 | 0.020 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 590 | 0.020 |
Why?
|
| DNA, Fungal | 1 | 2012 | 60 | 0.020 |
Why?
|
| Fungal Proteins | 1 | 2013 | 145 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1133 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 255 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2025 | 9099 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1053 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 337 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1917 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 3830 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 3054 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 894 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1546 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 876 | 0.020 |
Why?
|
| Air Conditioning | 1 | 2009 | 6 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2009 | 40 | 0.020 |
Why?
|
| Genome, Human | 1 | 2014 | 823 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 159 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2009 | 56 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2009 | 179 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 192 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 251 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2484 | 0.020 |
Why?
|
| Interior Design and Furnishings | 1 | 2005 | 1 | 0.010 |
Why?
|
| Illinois | 1 | 2006 | 520 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 990 | 0.010 |
Why?
|
| Boutonneuse Fever | 1 | 1983 | 1 | 0.010 |
Why?
|
| Rickettsiaceae Infections | 1 | 1983 | 2 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1983 | 69 | 0.010 |
Why?
|
| Survival Rate | 1 | 2006 | 1948 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2441 | 0.010 |
Why?
|
| Prognosis | 2 | 2006 | 3911 | 0.010 |
Why?
|
| Siderosis | 1 | 1997 | 2 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Iron | 1 | 1997 | 174 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1997 | 988 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 7061 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 985 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1997 | 960 | 0.010 |
Why?
|
| Liver | 1 | 1997 | 1210 | 0.010 |
Why?
|
| Time Factors | 1 | 1997 | 5410 | 0.000 |
Why?
|